L'intérêt à découvert pour NRX Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de NRX Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

NRX Pharmaceuticals (NASDAQ:NRXP) Stock, Rapport sur les intérêts à découvert

NRX PHARMACEUTICALS INC

NRX Pharmaceuticals

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

<p>We are in the summer doldrums of sorts, at least when it comes to insider activity.</p>
<p>Insiders have taken their checkbook to the beach, the mountains or just locked it away for a staycation.</p>
<p>What they have not been doing is buying much stock in the companies they own recently.</p>
<p>It might be the political turmoil surrounding global trade and the various conflicts going on around the world.</p>
<p>It might be the heat and humidity that are keeping insiders on the sideline.</p>
<p>It might be (and probably is) the high valuation and momentum driven stock market that is keeping insiders on the sideline for now.</p>
<p>Whatever the reason we are experiencing one of the lowest levels of insider activity in a long time.</p>
<p>While most insiders are sitting out the summer there are a few special situations developing as insider activists are making moves on a small handful of targets.</p>
<p>Some special situations make headlines. Others move silently, threading their way through SEC filings and obscure corners of the market before breaking out into full view. Right now, we are tracking three such setups distinct in style but unified by one trait: control is changing hands or about to, and the implications for shareholders are real. Whether the story is told by insiders aiming to go private, activists knocking on the door, or new players quietly surfacing with strategic intent, the next phase in each of these companies could be highly consequential.</p>
<p>Let us begin with the most advanced of the three.</p>
<p><strong>Fonar Corporation (Ticker: FONR): An Inside Job</strong><br />Fonar is not a household name unless you have had the misfortune of needing an upright MRI. It is a niche medical device company, the only one in the world producing vertical position MRI scanners, and it has remained quietly profitable for years without a hint of debt on its books. This month, a 13D filing laid out what longtime observers suspected was coming: a management led effort to take the company private.</p>
<p>The group behind the filing controls 48.1% of the company and includes CEO Timothy Damadian, his brother Joseph Damadian, COO Timothy Bonanni, and several longtime employees and directors. Most of the shares were acquired long ago through inheritance, compensation grants, or personal investment and the group has not made any market purchases in recent months. But what matters is not how they acquired the shares. It is what they plan to do with them.</p>
<p>The 13D makes it clear: the insiders have formed an acquisition entity and have approached the board about a going private transaction. No terms have been disclosed, but the writing is on the wall. Fonar has always been a tightly controlled entity. Now that control may be used to reshape the capital structure completely. Whether this leads to a fair offer and a clean exit for minority holders or a protracted negotiation that tests governance standards remains to be seen. Either way, the special situation is live.</p>
<p><strong>Jack in the Box (Ticker: JACK): Burgers, Boardrooms, and a Poison Pill</strong><br />Fonar&#8217;s special situation is driven from the inside. Jack in the Box&#8217;s is coming from the outside and the response has been classic boardroom defense.</p>
<p>Sardar Biglari, known for his aggressive value investing and his long campaign at Cracker Barrel, has disclosed a 9.98% stake in Jack in the Box and filed a 13D. That is just shy of the newly installed poison pill threshold of 12.5% the company adopted days later. The message from Jack&#8217;s board is clear: &#8220;Not so fast.&#8221;</p>
<p>Jack is no stranger to challenges. The fast food chain is in the middle of a multiyear turnaround dubbed &#8220;Jack on Track,&#8221; which includes closing 200 underperforming stores, focusing on digital transformation, and possibly divesting Del Taco. Biglari&#8217;s entrance adds pressure and scrutiny, particularly as management tries to execute a complex operational plan with significant real estate implications.</p>
<p>The 13D does not outline specific proposals yet, but the playbook is familiar. Biglari rarely stays quiet. If Jack&#8217;s performance does not improve quickly, or if a meaningful buyback or asset monetization is not proposed, the next proxy season could get interesting. For now, the company is hoping the pill buys them time. Investors should watch Biglari&#8217;s next filing closely for signs of escalation.</p>
<p><strong>Brera Holdings (Ticker: BREA): A Subtle Stake with Strategic Intent<br /></strong>And then there is Brera Holdings, a microcap that rarely crosses the radar of institutional investors. But that might change.</p>
<p>On July 14, a group of seven individual investors filed a 13D disclosing a collective 6.7% stake in Brera&#8217;s Class B shares. The names include Guy Hirsch, Ron Sade, and Stanislav Oskin figures with connections to digital assets and international finance. They did not just file a passive disclosure. The group explicitly stated they are engaging the board regarding strategic direction, crypto treasury policy, and board representation. In other words, this is activist with a lowercase &#8220;a,&#8221; but activist, nonetheless.</p>
<p>Brera is not a well-covered company, but it is positioning itself as a fintech and digital asset management platform. The company&#8217;s public float is tiny, and its Class B shares carry voting rights that could allow a small, coordinated group to exert real influence. The 13D group acquired shares directly from the issuer in June and appears to be laying the groundwork for a deeper involvement in shaping company strategy.</p>
<p>The outcome here is far from certain. Brera could be another forgotten microcap that drifts sideways. Or it could become a proving ground for a new generation of operator activists experimenting with governance in the post crypto world. Either way, the seeds of change have been planted.</p>
<p><strong>Three Quiet Storms, One Theme: Control<br /></strong>Each of these situations represents a different phase of the same cycle. At Fonar, the people who already run the business are preparing to buy the rest of it. At Jack in the Box, a known activist has moved in, forcing the board to defend its strategic plan. At Brera, a group of outsiders is probing for influence with board level ambitions and thematic ideas. None of these companies are making headlines on CNBC, but each could be offering the kind of asymmetrical outcomes that deep value investors, special situation hunters, and control premium seekers live for.</p>
<p>If you believe in the power of control, governance, and the alignment of incentives, then these are the setups to watch. The fights are not yet public, but the filings say more than enough. These are not random stake disclosures. They are warning shots. Or, depending on your view, invitations.</p>


Opinion

BREA

FONR

JACK

Alpha Buying: The Quietest Insider Summer Still Brought These Power Plays

<p>Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) will release its quarterly earnings report on Friday, 2025-07-18. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Autoliv to report an <strong>earnings per share</strong> (EPS) of $2.00.</p>
<p>The announcement from Autoliv is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.48, leading to a 0.54% drop in the share price on the subsequent day.</p>
<p>Here's a look at Autoliv's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.67</td>
<td>2.83</td>
<td>1.95</td>
<td>2.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.15</td>
<td>3.05</td>
<td>1.84</td>
<td>1.87</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-5.0%</td>
<td>6.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752761030_0.png" alt="eps graph" /></p>
<h3>Market Performance of Autoliv's Stock</h3>
<p>Shares of Autoliv were trading at $116.81 as of July 16. Over the last 52-week period, shares are up 19.56%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Autoliv</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Autoliv.</p>
<p>Analysts have given Autoliv a total of 9 ratings, with the consensus rating being Outperform. The average one-year price target is $119.78, indicating a potential 2.54% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of BorgWarner, Lear and Gentex, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for BorgWarner, with an average 1-year price target of $38.55, suggesting a potential 67.0% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Lear, with an average 1-year price target of $111.83, suggesting a potential 4.26% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Gentex, with an average 1-year price target of $24.33, suggesting a potential 79.17% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for BorgWarner, Lear and Gentex, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoliv</td>
<td>Outperform</td>
<td>-1.41%</td>
<td>$478M</td>
<td>7.22%</td>
</tr>
<tr>
<td>BorgWarner</td>
<td>Neutral</td>
<td>-2.23%</td>
<td>$639M</td>
<td>2.79%</td>
</tr>
<tr>
<td>Lear</td>
<td>Neutral</td>
<td>-7.24%</td>
<td>$359.20M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Gentex</td>
<td>Neutral</td>
<td>-2.28%</td>
<td>$191.73M</td>
<td>3.78%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Autoliv ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Unveiling the Story Behind Autoliv</h3>
<p>Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.</p>
<h3>Autoliv: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Autoliv's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-1.41%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Autoliv's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.22%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Autoliv's ROA excels beyond industry benchmarks, reaching <strong>2.1%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Autoliv's debt-to-equity ratio is below the industry average at <strong>0.96</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/ALV/earnings"><strong>To track all earnings releases for Autoliv visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Earnings Preview: Autoliv

<p>Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) is gearing up to announce its quarterly earnings on Friday, 2025-07-18. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Comerica will report an <strong>earnings per share</strong> (EPS) of $1.23.</p>
<p>Anticipation surrounds Comerica's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS beat by $0.12 in the last quarter, leading to a 1.66% increase in the share price on the following day.</p>
<p>Here's a look at Comerica's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.13</td>
<td>1.26</td>
<td>1.16</td>
<td>1.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.25</td>
<td>1.20</td>
<td>1.37</td>
<td>1.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752761003_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Comerica were trading at $61.14 as of July 16. Over the last 52-week period, shares are up 22.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CMA/earnings"><strong>To track all earnings releases for Comerica visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Comerica's Earnings

<p><strong>Huntington Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) is set to give its latest quarterly earnings report on Friday, 2025-07-18. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Huntington Bancshares will report an <strong>earnings per share</strong> (EPS) of $0.36. </p>
<p>The announcement from Huntington Bancshares is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.03 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at Huntington Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.31</td>
<td>0.32</td>
<td>0.30</td>
<td>0.28</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>0.34</td>
<td>0.33</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>1.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760982_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Huntington Bancshares were trading at $16.64 as of July 16. Over the last 52-week period, shares are up 12.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HBAN/earnings"><strong>To track all earnings releases for Huntington Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HBAN

Earnings Preview For Huntington Bancshares

News

Principal Financial Group Collaborates With FuturePlan To Enhance Integration Of Recordkeeping, Investment, And TPA Services

<p><strong>SLB</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is set to give its latest quarterly earnings report on Friday, 2025-07-18. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that SLB will report an <strong>earnings per share</strong> (EPS) of $0.74. </p>
<p>The announcement from SLB is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $0.02 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at SLB's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.74</td>
<td>0.90</td>
<td>0.88</td>
<td>0.83</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.72</td>
<td>0.92</td>
<td>0.89</td>
<td>0.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>6.0%</td>
<td>-5.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760972_0.png" alt="eps graph" /></p>
<h3>Tracking SLB's Stock Performance</h3>
<p>Shares of SLB were trading at $34.59 as of July 16. Over the last 52-week period, shares are down 30.14%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Insights Shared by Analysts on SLB</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on SLB.</p>
<p>SLB has received a total of 12 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $47.08, the consensus suggests a potential 36.11% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Baker Hughes, Halliburton and TechnipFMC, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Baker Hughes, with an average 1-year price target of $46.91, suggesting a potential 35.62% upside.</li>
<li>Analysts currently favor an Buy trajectory for Halliburton, with an average 1-year price target of $27.27, suggesting a potential 21.16% downside.</li>
<li>Analysts currently favor an Outperform trajectory for TechnipFMC, with an average 1-year price target of $40.75, suggesting a potential 17.81% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Baker Hughes, Halliburton and TechnipFMC, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLB</td>
<td>Outperform</td>
<td>-2.49%</td>
<td>$1.61B</td>
<td>3.92%</td>
</tr>
<tr>
<td>Baker Hughes</td>
<td>Outperform</td>
<td>0.14%</td>
<td>$1.48B</td>
<td>2.37%</td>
</tr>
<tr>
<td>Halliburton</td>
<td>Buy</td>
<td>-6.67%</td>
<td>$879M</td>
<td>1.95%</td>
</tr>
<tr>
<td>TechnipFMC</td>
<td>Outperform</td>
<td>9.38%</td>
<td>$464.90M</td>
<td>4.61%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>SLB ranks at the bottom for Revenue Growth and Gross Profit, with negative growth rates and lower profit figures compared to peers. SLB also has the lowest Return on Equity among the group. Overall, SLB's performance lags behind its peers in key financial metrics.</p>
<h3>Unveiling the Story Behind SLB</h3>
<p>SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts roughly $3 billion in digital-related revenue.</p>
<h3>SLB: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, SLB faced challenges, resulting in a decline of approximately <strong>-2.49%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> SLB's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>9.39%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.92%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.63%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.72</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/SLB/earnings"><strong>To track all earnings releases for SLB visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: SLB's Earnings Outlook

<p><strong>Regions Finl</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) is set to give its latest quarterly earnings report on Friday, 2025-07-18. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Regions Finl will report an <strong>earnings per share</strong> (EPS) of $0.56. </p>
<p>Regions Finl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.03, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at Regions Finl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.55</td>
<td>0.53</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.54</td>
<td>0.59</td>
<td>0.57</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760959_0.png" alt="eps graph" /></p>
<h3>Performance of Regions Finl Shares</h3>
<p>Shares of Regions Finl were trading at $24.08 as of July 16. Over the last 52-week period, shares are up 10.03%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RF/earnings"><strong>To track all earnings releases for Regions Finl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Regions Finl

<p>Truist Securities  analyst Matthew Coad   maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Buy and raises the price target from $181 to $185.</p>


Price Target

Analyst Ratings

Truist Securities Maintains Buy on Fiserv, Raises Price Target to $185

<p>Eighteen-year-olds are in one of the best spots to make long-term investments. They don't have as many financial responsibilities as parents and can wait several years before they even have to think about selling some of their stocks.&nbsp;</p>
<p>However, being young also gives them less experience.&nbsp; That's why an 18-year-old who's interested in investing <a href="https://www.reddit.com/r/personalfinance/comments/1lqn2ne/any_advice_for_an_18_year_old/">turned to Reddit for some suggestions</a>.</p>
<p>"I'd like to get into investing," the recent high school graduate shared in the Personal Finance subreddit.</p>
<p><strong>Don't Miss:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-offer">Accredited investors can claim pre-IPO shares of Mode Mobile for just $0.30</a></strong><strong>—with up to 120% bonus shares—before this Uber-style disruption hits the public markets</strong></li>
<li><strong>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning"><strong>Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</strong></a> – no cost, no obligation.</strong></li>
</ul>
<p>The 18-year-old currently has savings in a Wealthfront account, which has a 4.00% APY. Redditors offered several suggestions on how to approach investing.</p>
<h2 class="wp-block-heading">Start Contributing To A Retirement Account Now</h2>
<p>Many Redditors encouraged the 18-year-old to contribute to retirement accounts. If the employer offers retirement accounts, the young Redditor should aim to max out the account.</p>
<p>However, you don't need an employer-sponsored retirement plan to get started. Anyone can create an individual retirement account, even if they are doing freelance work. These tax-advantaged accounts let you accumulate assets while reducing your tax bill.</p>
<p>Roth IRAs make more sense for people who aren't earning high incomes. Your account contributions get taxed, but you don't pay any taxes on withdrawals, dividends, or capital gains. Traditional IRAs let you make tax-free contributions, but you get taxed on the way out. These accounts are better for people who have high incomes.</p>
<p><strong>Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air"><strong>And You Can Invest At Just $6.37/Share</strong></a></strong></p>
<h2 class="wp-block-heading">Learn How To Start A Business</h2>
<p>Although investing often revolves around stocks and real estate, you can also invest in yourself and learn how to start a business. One Redditor encouraged the 18-year-old to go in that direction.</p>
<p>The original poster currently works full-time at an HVAC company. While the industry can pay well, your earnings potential will skyrocket if you start a business instead of relying on an employer's paychecks.</p>
<p>"​​Learn everything you can about not only HVAC but how to run an HVAC business! You'll do really well by the time you're 30!" one commenter suggested.</p>
<p>Starting a business isn't only good for boosting your earnings. It also diversifies your income and reduces financial risk once you establish your business. When you own a business, you're not at the mercy of an employer potentially laying you off due to a slow economy. You have more control over your company's outcomes and can tap into new markets to increase revenue.</p>
<p><strong><em>See Also: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?"><strong><em>You Can Become an Investor for Just $500.25</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">Focus On Index Funds</h2>
<p>Most 18-year-olds don't know much about investing. It's not taught in most schools, and you learn the most about investing by experiencing it.</p>
<p>Instead of picking individual stocks, the Redditor can focus on an index fund that tracks an established benchmark like the S&amp;P 500. These funds typically have low expense ratios and tend to outperform most active investors.</p>
<p>Index funds can produce much higher returns than a savings account that offers 4.00% APY. Plus, you won't be taxed on any of your unrealized capital gains. Any qualified dividends also get taxed at better rates than the interest payments you receive from a high-yield savings account. Stocks are riskier than savings accounts, but the 18-year-old has a lot of time to wait out any corrections and volatility.</p>
<p><strong>Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"><strong> </strong><strong>Here&#8217;s how you can earn passive income with just $10.</strong></a></strong></p>
<p><em><strong>Image: Shutterstock</strong></em></p>


Personal Finance

An 18-Year-Old Asks Reddit For Financial Advice: 'I'd Like To Get Into Investing'

<p>Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) is gearing up to announce its quarterly earnings on Friday, 2025-07-18. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Ally Financial will report an <strong>earnings per share</strong> (EPS) of $0.79.</p>
<p>The announcement from Ally Financial is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.16, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Ally Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.42</td>
<td>0.57</td>
<td>0.53</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.58</td>
<td>0.78</td>
<td>0.95</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760940_0.png" alt="eps graph" /></p>
<h3>Performance of Ally Financial Shares</h3>
<p>Shares of Ally Financial were trading at $39.33 as of July 16. Over the last 52-week period, shares are down 4.95%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Ally Financial</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ally Financial.</p>
<p>A total of 7 analyst ratings have been received for Ally Financial, with the consensus rating being Buy. The average one-year price target stands at $43.86, suggesting a potential 11.52% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Enova International and Dave, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Enova International, with an average 1-year price target of $129.5, suggesting a potential 229.27% upside.</li>
<li>Analysts currently favor an Buy trajectory for Dave, with an average 1-year price target of $234.73, suggesting a potential 496.82% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Enova International and Dave, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaspi.kz</td>
<td>Outperform</td>
<td>48.67%</td>
<td>$430.02B</td>
<td>15.62%</td>
</tr>
<tr>
<td>Enova International</td>
<td>Buy</td>
<td>22.24%</td>
<td>$345.64M</td>
<td>6.10%</td>
</tr>
<tr>
<td>Dave</td>
<td>Buy</td>
<td>46.65%</td>
<td>$100.87M</td>
<td>15.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ally Financial ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.</p>
<h3>Unveiling the Story Behind Ally Financial</h3>
<p>Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.</p>
<h3>Breaking Down Ally Financial's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Ally Financial's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-20.15%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ally Financial's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-14.42%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ally Financial's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.15%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ally Financial's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.13%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ally Financial's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.6</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ALLY/earnings"><strong>To track all earnings releases for Ally Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ALLY

Earnings Preview For Ally Financial

<p>22 analysts have expressed a variety of opinions on e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">14</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated e.l.f. Beauty and provided 12-month price targets. The average target is $112.45, accompanied by a high estimate of $150.00 and a low estimate of $75.00. This current average reflects an increase of 17.14% from the previous average price target of $96.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760934_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive e.l.f. Beauty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$114.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to e.l.f. Beauty. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of e.l.f. Beauty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of e.l.f. Beauty's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ELF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on e.l.f. Beauty analyst ratings.</strong></a></p>
<h2>All You Need to Know About e.l.f. Beauty</h2>
<p>e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.</p>
<h3>A Deep Dive into e.l.f. Beauty's Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> e.l.f. Beauty displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>3.58%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.49%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> e.l.f. Beauty's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.7%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.25%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.41</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing e.l.f. Beauty: Insights From 22 Financial Analysts

<p>Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is preparing to release its quarterly earnings on Friday, 2025-07-18. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Charles Schwab to report an <strong>earnings per share</strong> (EPS) of $1.07.</p>
<p>Anticipation surrounds Charles Schwab's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.03, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Charles Schwab's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>0.91</td>
<td>0.75</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.01</td>
<td>0.77</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760930_0.png" alt="eps graph" /></p>
<h3>Performance of Charles Schwab Shares</h3>
<p>Shares of Charles Schwab were trading at $91.26 as of July 16. Over the last 52-week period, shares are up 47.88%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Charles Schwab</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Charles Schwab.</p>
<p>A total of 18 analyst ratings have been received for Charles Schwab, with the consensus rating being Outperform. The average one-year price target stands at $98.0, suggesting a potential 7.39% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of LPL Finl Hldgs and Interactive Brokers Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for LPL Finl Hldgs, with an average 1-year price target of $437.3, suggesting a potential 379.18% upside.</li>
<li>Analysts currently favor an Buy trajectory for Interactive Brokers Group, with an average 1-year price target of $140.83, suggesting a potential 54.32% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for LPL Finl Hldgs and Interactive Brokers Group are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robinhood Markets</td>
<td>Buy</td>
<td>50.00%</td>
<td>$793M</td>
<td>4.22%</td>
</tr>
<tr>
<td>LPL Finl Hldgs</td>
<td>Outperform</td>
<td>29.56%</td>
<td>$966.40M</td>
<td>10.52%</td>
</tr>
<tr>
<td>Interactive Brokers Group</td>
<td>Buy</td>
<td>5.10%</td>
<td>$2.04B</td>
<td>4.85%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Charles Schwab ranks at the top for Revenue Growth among its peers, with a growth rate of 50.00%. It also leads in Gross Profit, generating $793M. However, it falls behind in Return on Equity, with a rate of 4.22%.</p>
<h3>Discovering Charles Schwab: A Closer Look</h3>
<p>Charles Schwab is one of the largest retail-oriented financial services companies in the US, with $10.1 trillion in client assets across its brokerage, banking, asset-management, custody, financial advisory, and wealth-management businesses at year-end 2024. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset-management segments. The firm is a dominant player in registered investment advisor custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.</p>
<h3>A Deep Dive into Charles Schwab's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Charles Schwab's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>18.02%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>32.08%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Charles Schwab's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>4.52%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Charles Schwab's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.38%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.99</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SCHW/earnings"><strong>To track all earnings releases for Charles Schwab visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SCHW

A Preview Of Charles Schwab's Earnings

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Sonic Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) in the last three months.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Sonic Automotive and provided 12-month price targets. The average target is $77.43, accompanied by a high estimate of $94.00 and a low estimate of $64.00. A decline of 1.99% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760919_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Sonic Automotive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$72.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Albanese</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sonic Automotive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sonic Automotive compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Sonic Automotive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Sonic Automotive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SAH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sonic Automotive analyst ratings.</strong></a></p>
<h2>Discovering Sonic Automotive: A Closer Look</h2>
<p>Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 15 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.</p>
<h3>Sonic Automotive: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Sonic Automotive's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>7.9%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Sonic Automotive's net margin is impressive, surpassing industry averages. With a net margin of <strong>1.93%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sonic Automotive's ROE excels beyond industry benchmarks, reaching <strong>6.56%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Sonic Automotive's ROA excels beyond industry benchmarks, reaching <strong>1.2%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Sonic Automotive's debt-to-equity ratio is below the industry average. With a ratio of <b>3.71</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


7 Analysts Assess Sonic Automotive: What You Need To Know

<p>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is preparing to release its quarterly earnings on Friday, 2025-07-18. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect American Express to report an <strong>earnings per share</strong> (EPS) of $3.86.</p>
<p>Investors in American Express are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.17, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at American Express's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.47</td>
<td>3.03</td>
<td>3.28</td>
<td>3.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.64</td>
<td>3.04</td>
<td>3.49</td>
<td>3.49</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760911_0.png" alt="eps graph" /></p>
<h3>Market Performance of American Express's Stock</h3>
<p>Shares of American Express were trading at $311.9 as of July 16. Over the last 52-week period, shares are up 29.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on American Express</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on American Express.</p>
<p>The consensus rating for American Express is Neutral, derived from 14 analyst ratings. An average one-year price target of $304.71 implies a potential 2.31% downside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Enova International and Dave, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Enova International, with an average 1-year price target of $129.5, suggesting a potential 58.48% downside.</li>
<li>Analysts currently favor an Buy trajectory for Dave, with an average 1-year price target of $234.73, suggesting a potential 24.74% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>In the peer analysis summary, key metrics for Enova International and Dave are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaspi.kz</td>
<td>Outperform</td>
<td>48.67%</td>
<td>$430.02B</td>
<td>15.62%</td>
</tr>
<tr>
<td>Enova International</td>
<td>Buy</td>
<td>22.24%</td>
<td>$345.64M</td>
<td>6.10%</td>
</tr>
<tr>
<td>Dave</td>
<td>Buy</td>
<td>46.65%</td>
<td>$100.87M</td>
<td>15.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>American Express ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Get to Know American Express Better</h3>
<p>American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. The firm operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.</p>
<h3>American Express's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining American Express's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>7.38%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> American Express's net margin excels beyond industry benchmarks, reaching <strong>15.04%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>8.3%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> American Express's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.92%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> American Express's debt-to-equity ratio is below the industry average. With a ratio of <b>1.69</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/AXP/earnings"><strong>To track all earnings releases for American Express visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


American Express's Earnings Outlook

Macro Economic Events

Econ #s

Economics

Retail Inventories Ex Auto (May) 0.2% Vs 0.2% Est.

<p>In the latest quarter, 35 analysts provided ratings for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">18</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $61.14, a high estimate of $125.00, and a low estimate of $10.00. This current average has decreased by 44.81% from the previous average price target of $110.79. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760907_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Sarepta Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$25.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$70.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Maintains</td>
<td>Sector Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$58.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$98.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$182.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sarepta Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sarepta Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sarepta Therapeutics analyst ratings.</strong></a></p>
<h2>All You Need to Know About Sarepta Therapeutics</h2>
<p>Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.</p>
<h3>Sarepta Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Sarepta Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>80.15%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-60.08%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sarepta Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-33.52%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Sarepta Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-12.05%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Sarepta Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <b>1.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SRPT

Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts

<p>In the last three months, 9 analysts have published ratings on Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $25.33, a high estimate of $30.00, and a low estimate of $21.00. Observing a downward trend, the current average is 1.13% lower than the prior average price target of $25.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760897_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Magnolia Oil &amp; Gas is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Peyton Dorne</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Peyton Dorne</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Magnolia Oil &amp; Gas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Magnolia Oil &amp; Gas compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Magnolia Oil &amp; Gas's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Magnolia Oil &amp; Gas's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MGY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Magnolia Oil &amp; Gas analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Magnolia Oil &amp; Gas</h2>
<p>Magnolia Oil &amp; Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.</p>
<h3>Key Indicators: Magnolia Oil &amp; Gas's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Magnolia Oil &amp; Gas's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>9.67%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>28.92%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Magnolia Oil &amp; Gas's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.27%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Magnolia Oil &amp; Gas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.56%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Magnolia Oil &amp; Gas's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.21</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 9 Analyst Ratings Have To Say About Magnolia Oil & Gas

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.0, a high estimate of $4.00, and a low estimate of $4.00. Staying constant with the previous average price target, the current average remains unchanged. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760887_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of BRC among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BRC. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of BRC compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of BRC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BRC's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BRCC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on BRC analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know BRC Better</h2>
<p>BRC Inc is a veteran-controlled company that serves premium coffee, content, and merchandise to active military, veterans, and first responders. It is committed to producing great coffee that consumers love, and high-quality merchandise that enables its community to showcase its brand. Its omnichannel distribution has three components: Direct to Consumer channel includes its e-commerce business, through which consumers order products online and products are shipped to them, Its wholesale channel includes products sold to an intermediary such as convenience, grocery, drug, and mass merchandise stores, who in turn sell those products to consumers, and Outpost channel includes revenue from its Company-operated and franchised Black Rifle Coffee retail coffee shop locations.</p>
<h3>Unraveling the Financial Story of BRC</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> BRC's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-8.56%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> BRC's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-3.21%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> BRC's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-23.72%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> BRC's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.28%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> BRC's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>8.92</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BRCC

What Analysts Are Saying About BRC Stock

<p>Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) will release its quarterly earnings report on Friday, 2025-07-18. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Truist Finl to report an <strong>earnings per share</strong> (EPS) of $0.93.</p>
<p>Investors in Truist Finl are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 0.0% drop in the share price on the following day.</p>
<p>Here's a look at Truist Finl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.87</td>
<td>0.88</td>
<td>0.91</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.87</td>
<td>0.91</td>
<td>0.97</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>6.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760885_0.png" alt="eps graph" /></p>
<h3>Tracking Truist Finl's Stock Performance</h3>
<p>Shares of Truist Finl were trading at $44.36 as of July 16. Over the last 52-week period, shares are up 5.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TFC/earnings"><strong>To track all earnings releases for Truist Finl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Truist Finl's Earnings Outlook

<p>During the last three months, 8 analysts shared their evaluations of Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $76.75, a high estimate of $90.00, and a low estimate of $65.00. This upward trend is evident, with the current average reflecting a 3.72% increase from the previous average price target of $74.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752760873_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Hasbro by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Perry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Stephen Laszczyk</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$79.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Keegan Cox</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hasbro. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hasbro compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Hasbro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Hasbro's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Hasbro analyst ratings.</strong></a></p>
<h2>Discovering Hasbro: A Closer Look</h2>
<p>Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has divested noncore lines from the tie-up. Furthermore, the addition of Dungeons &amp; Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.</p>
<h3>Financial Insights: Hasbro</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Hasbro's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>17.14%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.11%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Hasbro's ROE excels beyond industry benchmarks, reaching <strong>8.47%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Hasbro's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.59%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Hasbro's debt-to-equity ratio surpasses industry norms, standing at <strong>2.87</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Hasbro Through The Eyes Of 8 Analysts

Press Releases

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

Small Cap

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

"Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz"

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

AIFF

ARAI

CTOR

ILMN

NRXP

PNPNF

PRSO

SNYR

TSXV:PNPN

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Grace Therapeutics

Hyperion DeFi

IGC Pharma

Ikena Oncology

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Comments

NRX Pharmaceuticals

Intérêt court

NRX Pharmaceuticals (NASDAQ:NRXP) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL